BioWorld - Wednesday, June 17, 2026

Articles Tagged with ''Aduhelm''

Panel: Aduhelm win benefits AD space despite noise and hurdles

Jan. 11, 2022
By Randy Osborne
“There isn’t a better place to be” now than in Alzheimer’s disease (AD) drug development, said Phyllis Ferrell, global head of external engagement in AD and neurodegeneration at Eli Lilly and Co., during Biotech Showcase’s panel talk titled, “Aduhelm: Stimulating the Next Generation of AD Treatment.”
Read More

AZ’s Alexion buys rights to rare heart disease drug from Aduhelm discoverer Neurimmune for $760M

Jan. 7, 2022
By Richard Staines
Astrazeneca plc’s recently acquired Alexion Pharmaceuticals Inc. has signed a deal worth up to $760 million with Neurimmune AG, the Swiss biotech that discovered Alzheimer’s drug Aduhelm (aducanumab), buying rights to amyloidosis drug NI-006. While Biogen Inc.’s Aduhelm targets amyloid plaques thought to cause Alzheimer’s in the brain, the phase Ib drug in Alexion’s deal is intended to tackle the build-up of the rogue protein that causes heart disease caused by transthyretin amyloid cardiomyopathy (ATTR-CM).
Read More
EMA icons

EMA’s CHMP rejects Biogen’s application for European approval of Aduhelm in Alzheimer’s

Dec. 17, 2021
By Cormac Sheridan
DUBLIN – The EMA has rejected Biogen Inc.’s application for European Union approval of Aduhelm (aducanumab), its controversial Alzheimer’s disease drug. Its human medicines committee (CHMP) issued a negative opinion on Biogen’s dossier during its December meeting this week, stating that the data from the key studies submitted in support of the application “were conflicting and did not show overall that Aduhelm was effective at treating adults with early stage Alzheimer’s disease.”
Read More
Aduhelm product image
A look back as we head into 2022

Top Trends of 2021: Controversy much alive over Biogen’s Aduhelm; picture unclear for other AD prospects

Dec. 9, 2021
By Randy Osborne
In 2021, no drug approval garnered as much attention and debate as Biogen Inc.’s Aduhelm (aducanumab). The FDA’s surprise, accelerated approval of Aduhelm for Alzheimer’s disease flew in the face of the recommendation by an advisory committee, causing a stir that included the resignation of three adcom members, along with publicly made claims that the company’s relationship with regulators had become too cozy.
Read More
U.S. Capitol building

Senators pressured to pass drug pricing reforms in spending bill

Dec. 6, 2021
By Mari Serebrov
With the $2 trillion Build Back Better spending bill held up in the U.S. Senate, President Joe Biden took to his public microphone Dec. 6 to call on senators to pass the bill that will permit Medicare negotiation of certain prescription drug prices, impose an excise tax on drug companies that raise the price of their products beyond inflation and set a monthly cap on cost-sharing for insulin.
Read More
Biogen logo

Biogen knocked by ‘negative trend vote’ for Alzheimer’s drug in Europe

Nov. 17, 2021
By Jennifer Boggs
A European approval for Alzheimer’s drug aducanumab by year-end looks even more in doubt. A week after being called in before the EMA’s Committee for Medicinal Products for Human Use (CHMP) for an oral explanation of the trial data, Biogen Inc. said it received a “negative trend vote” on the marketing authorization application. A formal opinion by the CHMP is expected at its December meeting, but analysts are not optimistic.
Read More
‘Unforced error’

As EMA’s CHMP delays recommendation, US skepticism abides about Aduhelm approval

Nov. 12, 2021
By Anette Breindl
Technically speaking, the scientific community as a whole cannot say for sure whether and how well Aduhelm (aducanumab, Biogen Inc./Eisai, Co., Ltd.) works. After all, two years after the initial report of the Engage and Emerge data at the 2019 Clinical Trials in Alzheimer’s Disease (CTAD), the full trial data have still not been published in a peer-reviewed publication. Which, of course, is one of the problems with Aduhelm.
Read More